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Abstract
Background: Although numerous non-radioactive methods are in use to measure the catalytic activity of protein
kinases, most require specialized equipment and reagents and are not sufficiently sensitive for the detection of
endogenous kinase activity in biological samples. Kinases of the DYRK family have important functions in
developmental and pathophysiological processes in eukaryotic organisms including mammals. We aimed to
develop a highly sensitive, low-tech assay suitable to determine the activity of DYRK family kinases in tissues or
cells from diverse sources.
Results: Phosphorylation-site specific antibodies can be used to monitor the accumulation of the phosphorylated
product in kinase assays. We present a modified configuration of an enzyme-linked immunosorbent assay (ELISA)-
based kinase assay by using the phosphospecific antibody as the capture antibody. This assay format allowed the
detection of small amounts of phosphopeptide in mixtures with an excess of the unphosphorylated substrate
peptide (10 fmol phosphorylated peptide over a background of 50 pmol unphosphorylated peptide).
Consequently, low substrate turnover rates can be determined. We applied this method to the measurement of
endogenous DYRK1A activity in mouse heart tissue by immunocomplex kinase assay. Furthermore, we detected
DYRK1-like kinase activity in Xenopus laevis oocytes and identified this kinase as a DYRK1 isoform distinct from the
Xenopus DYRK1A ortholog.
Conclusion: We present a non-radioactive and highly sensitive method for the measurement of endogenous
activities of DYRKs in biological samples. Xenopus laevis oocytes contain an active DYRK1-related protein kinase
more similar to mammalian DYRK1B than DYRK1A.
Background
Most cellular processes are controlled by protein phos-
phorylation, and aberrant kinase activity has been impli-
cated in the etiology of a wide spectrum of diseases,
including cancer, chronic inflammatory disorders and
neurodegeneration. Studies on protein kinases are
important not only to elucidate molecular mechanisms
of signal transduction, but also for drug development.
Therefore, methods for measuring kinase activity and
for the identification of kinase inhibitors have become
increasingly important in biomedical research [1,2].
A widely employed type of assay is based on the use
of radioactively labelled ATP as phosphate donor and
subsequent detection of phosphate incorporation into a
protein or peptide substrate that contains the respective
kinase recognition motif [3,4]. This radiometric techni-
que is simple and suitable for detection of protein
kinase activity with high sensitivity but depends on
the use of radioactive isotopes (32P or 33P). Use of
radioactivity requires special handling, is associated with
inherent high costs of waste disposal, and restricts the
flexibility because of the short half life of 32P and 33P.
Furthermore, these assays are carried out at subphysio-
logical levels of ATP owing to the necessity of keeping
ATP levels, and thus the usage of radioisotopes, within
reasonable limits.
To circumvent these drawbacks, a wide variety of non-
radiometric techniques have been developed to measure
kinase activity, particularly for use in high throughput
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screening of kinase inhibitors (for recent reviews see
[1,2]. Several non-radiometric methods rely on anti-
bodies that can distinguish phosphorylated from unpho-
sphorylated forms of the kinase substrates [5]. Such
phosphorylation state-specific antibodies were first used
by Yano et al. [6] to measure protein kinase activity by
an ELISA method. In the original format, the in vitro-
kinase reaction takes place in the wells after coating of
the substrate to the surface of the microplate wells, and
the phosphorylated molecules are detected with a phos-
phospecific antibody [6-8]. The use of biotinylated pep-
tides allows the reaction to be performed in solution
before the substrate captured on streptavidin coated
plates [9,10]. An inherent drawback of the existing
ELISA-based assays is that in case of low enzymatic
turnover, the large amount of unphosphorylated sub-
strate will outcompete the phosphorylated substrate for
binding to the surface of the wells. This decreases the
overall sensitivity of the assay, and radiometric assays
are generally preferred for detecting endogenous kinase
activity.
Protein kinases of the DYRK family have been impli-
cated in a number of important biological processes in
diverse eukaryotic organisms, e.g. Pom1p in cell morpho-
genesis and mitotic entry in S. pombe [11,12], MBK2 in
oocyte maturation in C. elegans [13] and a DYRK1 iso-
form in Xenopus laevis oocyte maturation [14], minibrain
(MNB) in neurogenesis in Drosophila [15], and DYRK1A
in mammalian brain development and in neurodegenera-
tion [16,17]. Interestingly, alterations in neuronal devel-
opment were observed in mouse models both with a
selective gain or partial loss of function of Dyrk1A (for
recent reviews see [17,18]). This gene dosage effect
implies that subtle changes in the activity of this DYRK
family kinase can have severe consequences.
Many investigators are characterising the role of
DYRKs in various biological processes or their involve-
ment in human diseases [19-22]. For measuring the
activity of DYRKs, radiometric assays are presently the
standard in laboratory practice. We aimed at developing
a non-radiometric assay sufficiently sensitive to measure
kinase activity of endogenous DYRKs. By a modification
of the existing ELISA configurations, we accomplished
to reach a detection limit in the range of radiometric
assays. The sensitivity of the assay was sufficient to mea-
sure the activity of DYRK1A in mouse heart. Moreover,
we used the new method to characterize the activity of
a DYRK1 isoform expressed in Xenopus laevis oocytes.
Results
Development and characterization of the assay
Considering that the sensitivity in phospho-ELISA
methods is mainly limited by the number of substrate
binding sites available for immobilization, we reasoned
that this problem could be overcome by using the phos-
phospecific antibody for capturing the small amounts of
phosphopeptide from the complex reaction mixture. We
decided to use a substrate peptide mimicking the
sequence around Thr212 in the tau protein (also called
microtubule-associated protein tau, MAPT). This is a
well characterized phosphorylation site of DYRK1A
[23,24], and phosphospecific antibodies directed against
this site are commercially available. We used a biotiny-
lated substrate peptide to allow for colorimetric detec-
tion of the bound phosphopeptide with the help a
streptavidin-HRP conjugate (Figure 1A). Concentrations
of the capture antibody and the streptavidin-HRP conju-
gate were optimized to develop the standard protocol
used in all experiments shown here (see Methods
section).
We performed a titration experiment to determine the
key parameters of the assay, i.e. the power to discrimi-
nate between the phosphorylated and unphosphorylated
biotinylated tau peptide (hereafter referred to as
tau207-219), the absolute lower detection limit, and the
linear range of the assay. As shown in Figure 1B, the
detection limit was about 5-10 fmol phosphopeptide per
well. A comparable signal was obtained with 320 pmol
of the unphosphorylated peptide, indicating that this
combination of phosphospecific antibody and substrate
peptide offers excellent selectivity for the detection of
the phosphorylated substrate (~ 105-fold discrimination).
Saturation of the assay was reached at about 1 pmol of
phosphopeptide, but the linear plot (Figure 1C) illus-
trates that the useful measuring range was between 0.01
pmol and 0.1 pmol. Thus, the sensitivity of the ELISA
compares well with radiometric assays, where about 0.1
pmol of phosphopeptide can be routinely detected. For
comparison, we analysed the same concentrations of
phosphorylated and unphosphorylated tau207-219 in the
inverse configuration, in which the phosphospecific anti-
body was used to detect the biotinylated peptide after
binding to streptavidin-coated plates (Figure 1D). This
assay was much less sensitive (detection limit of 1 pmol
phosphorylated peptide) and suffered from crossreaction
of the antibody with the unphosphorylated peptide at
concentrations greater than ~ 40 pmol per well.
Next we tested whether small amounts of the phos-
phopeptide can be detected in mixtures with a large
excess of the unphosphorylated peptide. Although the
experiment shown in Figure 1B suggested that 50-100
pmol of unphosphorylated peptide should only margin-
ally contribute to the total signal, these concentrations
reduced signal intensities obtained with 10-1000 fmol
phosphopeptide (Figure 1E). We decided to apply a
maximum of 50 pmol total peptide per well in subse-
quent experiments, and to keep this amount constant in
all samples of an assay (including the standards).
Lilienthal et al. BMC Biochemistry 2010, 11:20
http://www.biomedcentral.com/1471-2091/11/20
Page 2 of 10
Measurement of DYRK1A kinase activity
We performed in vitro-kinase reactions with varying
concentrations of recombinant GST-DYRK1A-ΔC to
determine the minimal detectable amount of kinase
activity (Figure 2). The titration revealed a useable linear
measuring range between 10 and 100 μU kinase activity,
corresponding to 20-200 pg of the recombinant kinase.
This results is in the range that could be predicted from
the detection limit of the ELISA (> 10 fmol phospho-
peptide), because 10 μU of kinase should phosphorylate
300 fmol substrate within 30 min, given that a sample
of 1/10 of the reaction mix was loaded per well and that
the excess of unphosphorylated peptide does not
severely affect detection of the phosphopeptide (Figure
1E). A similar sensitivity was achieved for GST-DYRK2,
consistent with the previous finding that both DYRK1A
and DYRK2 can phosphorylate Thr212 in the tau pro-
tein [23].
Next we tested whether this sensitivity was sufficient
to detect endogenous activity of DYRK1A immunopreci-
pitated from mammalian tissue. We used mouse heart
for this experiment, because DYRK1A has recently been
Figure 1 Direct sandwich ELISA format for the detection of the phosphorylated DYRK substrate peptide tau207-219. A, Scheme
illustrating the principle of the assay. Bio, biotin; TMB, tetramethylbenzidine; HRP, horseradish peroxidase (coupled to streptavidin). B and C,
Titration of phosphorylated and unphosphorylated tau207-219. The wells were coated with 100 ng anti tau(pT212) and loaded with dilution series
of either phosphorylated or unphosphorylated tau207-219. The background signal from wells loaded only with the buffer was subtracted from all
values. A representative experiment of three is shown. Panel C presents the same data as in panel B with a linear x-axis to visualize the linear
range of the ELISA. The inset shows an enlargement of lower range. D, Titration of phosphorylated and non-phosphorylated tau207-219 on
streptavidin-coated wells. Detection was performed with primary anti-tau(pT212) antibody and secondary goat anti-rabbit antibody coupled to
HRP. The graph is representative of two experiments. E, Detection of phosphorylated tau207-219 in the presence of excess unphosphorylated
peptide. Different amounts of phosphorylated tau207-219 (0.01 pmol, 0.1 pmol, 1 pmol) were mixed with a dilution series of unphosphorylated
tau207-219 (12.5 - 100 pmol). Signals obtained in wells loaded only with the same amount of the unphosphorylated peptide were subtracted from
the read-out of the mixtures. The graph is representative of two experiments. In B-E, error bars indicate the difference between duplicate wells.
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identified as a negative regulator of cardiomyocyte
hypertrophy [25]. The lysate was used for parallel
immunoprecipitations with a DYRK1A-specific antibody
and anti FLAG antibody as a negative control. After the
washing steps, the resin of each sample was split and
subjected in parallel to a non-radiometric and a radio-
metric immunocomplex kinase assay. The activity of the
bound kinase was calculated from the amount of phos-
phate incorporation (radiometric assay) or by compari-
son with a standard curve (ELISA). The results in
Table 1 show that the ELISA method was sufficiently
sensitive to detect endogenous DYRK1A activity in
mouse heart, although background levels were some-
what higher than in the radiometric assay.
Activity measurements of a DYRK1-related kinase in
Xenopus laevis oocytes
DYRK kinases from distantly related organisms exhibit
high sequence conservation in the catalytic domain (e.g.
85% identity between human DYRK1A and the Droso-
phila kinase minibrain) and are thus likely to recognize
similar sequences in their substrates. Therefore, we rea-
soned that the ELISA assay established for mammalian
DYRK1A could also be useful to measure DYRKs in
other species. We decided to use Xenopus oocytes as a
model system to test this assumption, because DYRK1A
has been reported to play a role in oocyte maturation
[14]. Database searching revealed sequences of two
DYRK1 isoforms encoded by different genes (Table 2).
One of these kinases shows 97% of sequence identity
with human DYRK1A in the catalytic domain and can
be regarded as the Xenopus ortholog of DYRK1A
(xDYRK1A). The other one shows comparable sequence
similarity with human DYRK1A and DYRK1B in the
catalytic domain, but is much more similar to DYRK1B
than DYRK1A in the C-terminal domain (see Additional
file 1: Figure S1 for the complete sequence alignment).
For the purpose of this report, we designate the latter
kinase xDYRK1B.
The mRNA originally detected in Xenopus oocytes by
Qu et al. [14] corresponds to xDYRK1B (see discussion).
To immunoprecipitate this kinase, we took advantage of
a polyclonal antiserum we had previously raised against
a peptide with the sequence of the 15 C-terminal amino
acids of mouse DYRK1B [26], of which 9 are identical
with xDYRK1B (Figure 3A). To test whether this anti-
serum also recognized xDYRK1B, we overexpressed
xDYRK1B in mammalian cells. As shown in Figure 3B,
the antiserum was indeed suitable for immunoprecipita-
tion and subsequent immunodetection of recombinant
xDYRK1B by Western blot analysis. No band was
detected in a control immunoprecipitation with serum
taken from the same rabbit before immunization. The
Figure 2 Assay sensitivity. A, In vitro-kinase reactions were performed
with 50 μM tau207-219, 100 μM ATP and variable concentrations of GST-
DYRK1A-ΔC or GST-DYRK2 for 30 min at 30°C. Reactions
were stopped by addition of EDTA and peptide phosphorylation was
analysed by the ELISA method. Panels B and C show enlarged views of
the lower kinase concentration range. Error bars indicate the difference
between duplicate measurements.
Table 1 DYRK1A kinase activity in mouse heart
Phosphorylated peptide (pmol)
IP Specific
result*
relative
background
aDYRK1A aFLAG
Radiometric
assay
5.63 1.20 4.43 21%
ELISA 7.88 2.24 5.63 28%
*subtraction of background (phosphorylation in aFLAG sample)
Immunoprecipitates from mouse heart lysate were split and subjected either
to a radiometric or a non-radiometric kinase reaction each carried out under
the same conditions (100 μM ATP, 50 μM tau207-209, 30 min, 30°C). The
amounts of phosphorylated peptide were calculated from incorporation of 33P
or determined by ELISA using a standard curve. As a background control, a
parallel immunocomplex kinase assay was performed with anti-FLAG antibody
instead of the anti-DYRK1A antibody. Aliquots of kinase reactions were diluted
1:10 for the ELISA. Results are means of duplicate measurements.
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immunopurified protein contained immunodetectable
phosphotyrosine, a common feature of the members of
the DYRK family. Taking advantage of the fact that
mammalian and Xenopus DYRK1A have identical
sequences in the region corresponding to the immuno-
genic peptide (Figure 3A), we overexpressed GFP-
DYRK1A in Hela cells to assess whether the DYRK1B
antiserum might crossreact with xDYRK1A. Importantly,
anti DYRK1B did not immunoprecipate GFP-DYRK1A
(Figure 3C), implying that it specifically immunoprecipi-
tates xDYRK1B and not xDYRK1A from the oocytes.
We used the DYRK1B antibody for immunocomplex
kinase assays to determine whether unstimulated Xeno-
pus oocytes contained active xDYRK1B. First we deter-
mined the phosphorylation of tau207-219 by the
immunoprecipitates over time (Figure 4). Kinase activity
was well detectable in the anti DYRK1B immunoprecipi-
tates, with little background in the preimmune serum
control. We decided to use an incubation time of 30
min for the following assays because the turnover was
flattening after this time point. The detection of
xDYRK1B activity was reproduced in three independent
assays with different batches of oocytes and was also
confirmed in a radiometric assay with a different sub-
strate peptide (DYRKtide) (Table 3). In spite of this
unequivocal detection of active xDYRK1B in Xenopus
oocytes, we failed to detect the immunopreciptated
xDYRK1B on Western blots (data not shown),
apparently because the immunodetection of xDYRK1B
on Western blots was less sensitive than the assay of its
catalytic activity.
Discussion
In the present report we describe a simple and non-
radiometric assay sufficiently sensitive to measure endo-
genous activities of DYRKs in cell and tissue lysates. We
demonstrate the usefulness of the method by measuring
the activity of DYRK1A in mouse heart lysate and of a
novel DYRK1B-related kinase in Xenopus laevis oocytes.
The novel assay relies on the detection of the phos-
phorylated substrate peptide by a phosphospecific anti-
body in a direct sandwich ELISA configuration. Existing
phospho-ELISA procedures for in vitro-kinase assays
have been designed mainly for screening application of
protein kinase inhibitors, where recombinant kinases are
used and sensitivity is not a major issue (e.g. [7,8,10,27],
as well as many commercial assays). In our ELISA con-
figuration, we use the phospho-specific antibody as a
capturing antibody. This set-up has already been utilized
for the detection of phosphoproteins in cellular lysates,
where the sensitive detection of a small fraction of phos-
phoprotein is a key issue [5]. Here we show that this
configuration allows the detection of small amounts (10-
100 fmol) of phosphopeptide in reaction mixtures con-
taining a great excess of the unphosphorylated substrate.
The inverse configuration of the ELISA, in which the
biotinylated peptide was bound to streptavidin-coated
wells, was much less sensitive with a detection limit of
about 1 pmol phosphorylated peptide (Figure 1D). We
have not further investigated the reason for this differ-
ence, but we speculate that the high density of the bioti-
nylated peptide that is immobilized by the streptavidin,
as compared with the few phosphorylated molecules
that are captured by the phosphoantibody, impedes the
binding of the detection antibody to the epitope. Further
analysis of other peptide/antibody pairs will be necessary
to determine whether this difference between the two
configurations of the ELISA is generally valid.
Advantages of our method in comparison with other
kinase assays are i) the high sensitivity ii) the possibility to
use high ATP levels, iii) the avoidance of radioisotopes
and iv) the simple set-up, i.e. the independence of specia-
lized reagents (such as labelled tracers) or instruments.
Apart from the plate reader, the method basically requires
a high-quality phosphospecific antibody and a biotinylated
substrate peptide. A drawback of ELISAs in comparison
with radiometric assays is the semiquantitative nature with
respect to the determination of the amount of phosphate
incorporated into substrate. However, even radiometric
assays of kinase activities are only rarely evaluated in a
quantitative manner, because they frequently aim at the
comparison of kinase activities in different samples
Table 2 Characteristics of the two Xenopus DYRK1
isoforms
xDYRK1A xDYRK1B
Database entries
XenBasea gene symbol dyrk1a dyrk1a.2
UniProtb Q2TAE3 Q7ZXV4
UniGenec Xl.29801 Xl.5747
Expression clones used
IMAGE clone 5542675 4724858
GenBank acc. BC110968 BC044104
Protein characteristics
molecular mass 84 kDa 76 kDa
histidine repeatd His11 absent
Sequence identity with hDYRK1A
catalytic domain 97% 90%
C-terminal domain 85% <30%
Sequence identity with hDYRK1B
catalytic domain 84% 87%
C-terminal domain <30% 59%
a http://www.xenbase.org;
b http://www.uniprot.org
c http://www.ncbi.nlm.nih.gov/unigene
d Human DYRK1A contains a repeat of 13 consecutive histidines, human
DYRK1B contains no histidine repeat
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analysed in parallel. In addition, the ELISA allows for the
quantification of the DYRK activity in a given lysate by
relating samples to a phosphopeptide standard. A minor
limitation of the ELISA is the narrow linear range of
detection, which can make it necessary to determine a sui-
table dilution of the reaction mixes.
We show that the present assay with tau207-219 as the
substrate peptide can also be employed for measuring
the activity of DYRK2, a kinase with 46% sequence
identity with DYRK1A in the catalytic domain. Thr212
in tau has also been reported to be phosphorylated by
other kinases such as protein kinase A (PKA) and
cyclin-dependent kinase 5 (CDK5) [28,29]. This lack of
specificity precludes the use of this particular substrate
for assays of a specific kinase in cell lysates, but on the
other hand should allow its use for PKA and CDK5 in
Figure 3 Immunoprecipitation of xDYRK1B. A, C-terminal sequences of human and Xenopus DYRK1A and DYRK1B. Amino acids identical with
the immunogenic peptide used to raise the DYRK1B antibody are highlighted in bold. B, Immunoprecipitation of xDYRK1B. HeLa cells were
transiently transfected with expression plasmids for xDYRK1B, GFP-DYRK1B or the empty vector (control). After immunoprecipitation with
DYRK1B-specific antiserum (aD1B) or preimmune serum (Pre), bound proteins were subjected to Western blot analysis with a phosphotyrosine-
specific antibody (P-Tyr) and the DYRK1B antiserum as indicated. Detection of IgG is shown as a loading control. The asterisk marks an unspecific
band. C, Specificity of the DYRK1B antiserum. COS7 cells were transiently transfected with expression plasmids for the GFP fusion proteins of
mammalian DYRK1A or DYRK1B as indicated on top of the lanes. Aliquots of the whole cell lysates (input) or proteins eluted from the
immunoprecipitates (aD1B, Pre) were subjected to Western blot analysis with anti GFP and anti DYRK1B antibodies as indicated. Detection of IgG
is shown as a loading control.
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immunocomplex kinase assays. Obviously, the method
should be applicable for other protein kinases, pro-
vided that suitable substrate peptide sequences are
known and that the respective phosphoepitope-specific
antibodies are available. It should be noted that the
quality of the phosphospecific antibody is a critical
issue, because any binding of the unphosphorylated
peptide will directly affect the background and thereby
limit sensitivity.
The evolutionary conservation of the DYRK family
encouraged us to assess whether the ELISA could be
used for measuring the activity of non-mammalian
DYRKs. Given that in many species DYRKs are
involved in differentiation processes [11-13,30-33],
early Xenopus development is an interesting model sys-
tem to study the role of DYRKs in vertebrate embryo-
genesis. Here we have for the first time determined the
activity of a kinase related to mammalian DYRK1B
(designated xDYRK1B) in Xenopus laevis oocytes. In a
previous report, an mRNA for a DYRK1-releated
kinase has been identified in a microarray experiment
with mRNA from Xenopus laevis oocytes and been
designated “DYRK1A” [14]. However, the probe on the
array was derived from a Xenopus tropicalis expressed
sequence tag (TNeu006j18, GenBank acc. AL635205)
that is derived from the Dyrk1a.2 gene, which is more
closely related to DYRK1B (see Table 2). Surprisingly,
Qu et al. [14] used a polyclonal antibody directed
against the C-terminus of human DYRK1A to detect a
90-kD band in lysates of matured oocytes. These
results may suggest that both xDYRK1A and xDYRK1B
are expressed in Xenopus oocytes. Our attempts to
immunoprecipitate xDYRK1A from the oocyte lysates
remained unsuccessful (data not shown), but it is pos-
sible that the monoclonal anti human DYRK1A anti-
body that we used (from Abnova, Taipei, Taiwan) does
not recognize xDYRK1A. Further studies will be neces-
sary to dissect the roles of xDYRK1A and xDYRK1B in
Xenopus development.
Conclusion
The use of a phosphospecific capture antibody in
ELISA-based kinase assays allows for the sensitive mea-
surement of endogenous DYRK activity in diverse biolo-
gical samples. With the help of this method, kinase
activity of DYRK1B was detected in Xenopus laevis
oocytes. We expect that this assay should prove useful
for the study of kinase functions in various model
systems.
Methods
Peptides and antibodies
A biotinylated substrate peptide mimicking the sequence
around Thr212 of the tau protein (Biotin-Ttds-
GSRSRTPSLPTPP-NH2, Thr212 is underlined, where
Ttds is a proprietary linker) was selected from the Single
Kinase Substrate Peptides commercially available from
JPT Peptide Technologies (Berlin, Germany). For use in
standard curves, a phosphorylated version was custom
synthesized by Eurogentec (Seraing, Belgium). The opti-
mized substrate peptide DYRKtide and the rabbit anti-
body directed against the C-terminus of human
DYRK1B have been described previously [26,34]. The
following antibodies were obtained from commercial
sources: rabbit anti TAU(pT212) antibody (Cat. No. 44-
740G; Invitrogen, Carlsbad, CA), mouse monoclonal
antibodies for phosphotyrosine (PY99, Santa Cruz Bio-
technology, Santa Cruz, CA), FLAG epitope (FLAG-M2,
Sigma, Munich, Germany) and DYRK1A (clone 7D10;
Abnova, Taipei City, Taiwan), and goat GFP-specific
antibody (Rockland, Gilbertsville, PA).
Figure 4 Immunocomplex kinase assay of xDYRK1B from Xenopus
laevis oocytes. Xenopus oocytes were lysed and the lysate was
subjected to immunoprecipitation with either DYRK1B antiserum or
preimmune serum (aD1B, Pre). Aliquots from immunocomplex kinase
reactions (100 μM ATP, 50 μM tau207-219, 30°C, total volume of 50 μL)
were taken at different times and the amounts of phosphorylated
tau207-219 were determined by the ELISA method with the help of a
standard curve. Error bars represent the difference between the
duplicate measurements.
Table 3 xDYRK1B kinase activity in Xenopus laevis
oocytes
Phosphorylated peptide (pmol)
IP (antibody) ELISA-based assay (n = 3) Radiometric assay
(n = 1)
1 2 3 Mean ± S.D.
Pre-immune 0.30 1.23 1.27 0.93 ± 0.55 0.15
aDYRK1B 6.19 8.19 11.34 8.57 ± 2.60 3.37
Immunocomplex kinase assays were performed with lysates of about 100 μl
settled oocytes per assay. Results of three independent ELISA assays (1-3) with
tau207-219 and one radiometric assay with DYRKtide are reported.
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Preparation of mouse heart and Xenopus oocyte lysates
Hearts from TW-104 mice were weighed and 2 ml of
lysis buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl,
0.5% NP-40, 15% glycerol, 1 mM EDTA, 1 mM NaF, 1
mM Na3VO4, 10 μg/ml aprotinin, 10 μg/mL pepstatin,
10 μg/mL leupeptin, 1 μL PMSF) were added per 400
mg of tissue. The hearts were cut into small pieces, sub-
jected to 10 strokes of medium rpm (stage 6 out of 10)
in a Potter Elvehjem homogenizer, and the homogenates
were then sonified for 20 s. After centrifugation
(21,000 g, 4°C, 10 minutes), the supernatant was taken
and stored at -80°C. The lysates were cleared by pre-
incubation for 30 minutes with 30 μL protein G agarose
(EZview™ Red Protein G Affinity Gel, Sigma, Munich,
Germany) and subsequent centrifugation before the
supernatant was taken for immunoprecipitations. Follicle
cell-free oocytes of oogenesis stages V or VI from Xeno-
pus laevis [35] were kindly provided by the members of
the Schmalzing group in the Institute of Pharmacology.
The oocytes were lysed in 4 volumes of lysis buffer by
up-and-down pipetting, and the lysates were cleared by
repeated centrifugation to remove lipids and insoluble
debris.
Immunoprecipitation
For the immunoprecipitation from heart lysates, 1 μg
monoclonal anti DYRK1A or 1 μg anti-FLAG antibody
were added to a volume of lysate containing 1 mg of
total protein. For the oocyte experiments, the amount of
lysate derived from a volume of 100 μl settled oocytes
was used for immunoprecipitation with either 1 μg anti
DYRK1A antibody, 1 μl anti DYRK1B serum [26] or 1
μl non-reacting serum (preimmune serum of the same
rabbit used to raise the DYRK1B-specific serum).
Immuncomplexes were captured by over-night incuba-
tion with protein G agarose at 4°C in an end-over-end
rotator. After washing the agarose beads twice with TBS
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA)
supplemented with 0.1% Igepal CA-630, twice with TBS
without Igepal and once with kinase buffer, bound
immunocomplexes were assayed for in vitro-kinase
activity (see below). In some experiments, the affinity
matrix was divided equally between two test tubes dur-
ing the last washing step to allow for the direct compar-
ison of radioactive and non-radioactive assay.
Cell culture and transfection
HeLa cells were cultured in Quantum 101 Medium for
HeLa cells (PAA Laboratories, Pasching, Austria) and
COS7 cells in DMEM medium supplemented with 10%
fetal calf serum (PAA) at 37°C in a humidified 5% CO2
atmosphere. Transient transfections were performed
using the FuGENE HD transfection reagent (Roche
Molecular Biochemicals, Mannheim, Germany).
Expression clones for GFP-DYRK1A and GFP-DYRK1B
(p69 splicing variant) have been described previously
[26,36]. An expression clone for untagged full length
xDYRK1B (IMAGE clone 4724858) was obtained from
Imagenes (Berlin, Germany).
Western blotting
After washing the immunoprecipitates with TBS, bound
proteins were eluted with Laemmli sample buffer, sepa-
rated by SDS-PAGE (7%) and blotted onto nitrocellulose
membranes. Immunodetection with commercial anti-
bodies was performed according to the supplier’s
instructions. The DYRK1B antiserum was used at a dilu-
tion of 1:5000 for 2 h at room temperature, and the TBS
for the washes following incubation with the primary
antibody was supplemented with 0.1% SDS to reduce
non-specific binding [26]. Western blots were developed
using horseradish peroxidase-coupled secondary antibo-
dies and chemiluminescence detection. The Clean-Blot
IP Detection Reagent (Thermo Scientific, Rockford, IL)
was used as a secondary antibody when proteins were
immunodetected with the same antibody used for
immunoprecipitation.
Kinase assays
Recombinant glutathione S-transferase (GST) fusion
proteins of rat DYRK1A-ΔC and human DYRK2 were
prepared as described previously [34,36]. One unit of
kinase activity was defined as the amount of enzyme
that catalyzed the phosphorylation of 1 nmol DYRKtide
per min at 30°C in kinase buffer (25 mM Hepes, pH 7.0,
5 mM MgCl2, 0.5 mM dithiothreitol).
To determine the assay sensitivity (Figure 2), reactions
were performed in a total volume of 10 μl with variable
amounts of the recombinant kinase, 50 μM tau207-219
and 100 μM ATP at 30°C for 30 min. Reactions were
stopped by addition of 10 μl 10 mM EDTA and stored
at -20°C until analysis by ELISA.
To prepare phosphorylated tau207-219 for the use in
the ELISA (Figure 1), we aimed to achieve maximal
phosphorylation by incubating 2.5 nmol tau207-219 with
an excess of active kinase (4 mU/μL GST-DYRK1A-ΔC)
in the presence of 0.82 mM ATP. The reaction mixture
was incubated for 2 hours, and the same amount of
kinase was supplemented after one hour. Total incor-
poration of phosphate was determined in a parallel reac-
tion that was incubated in the presence of [g-33P]ATP
under identical conditions. All other kinase assays were
incubated for 30 min at 30°C.
Immunocomplex kinase assays were carried out in a
total reaction volume of 50 μl in kinase buffer, 100 μM
ATP and 50 μM tau207-219 at 30°C for 30 min and
stopped by addition of 50 μL 10 mM EDTA. Samples
were stored at -20°C until evaluation by ELISA.
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Radiometric assays were run in the presence of [g-33P]
ATP (~ 2000 cpm/pmol). Incorporation of 33P into the
biotinylated tau peptide was determined by spotting ali-
quots of the reaction mix onto a streptavidin membrane
(SAM2 Biotin Capture Membrane, Promega, Mannheim,
Germany), which was then washed as described by the
manufacturer and evaluated by scintillation counting.
Radiometric immunocomplex kinase assays with the
substrate peptide DYRKtide (at 100 μM) were run with
10 μM ATP as described before [37].
Direct Sandwich ELISA
MaxiSorp F96 MicroWell™ Plates (Nunc, Langenselbold,
Germany) were coated with 100 ng/well TAU(pT212)
antibody at 4°C overnight. To keep the antibody con-
sumption low, we used 100 ng/well of capturing antibody
for coating in the standard protocol, although 200 ng/
well gave a slightly higher readout (1.2-fold). After block-
ing for 1 hour with 200 μl/well 2% (w/v) bovine serum
albumin (fraction V, modified Cohn, Calbiochem) in
phosphate buffered saline (PBS) (140 mM NaCl, 3 mM
KCl, 8 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), the
antigen was added in a volume of 100 μL/well and the
plates were incubated for 2 h at room temperature.
Bound antigen was detected with streptavidin-HRP con-
jugate (Pierce, Rockford, IL; 100 μL/well, 2 h at room
temperature; 25 ng/ml) and subsequent incubation with
100 μL/well TMB (3,3′,5,5′-tetramethylbenzidine) sub-
strate solution until colour development was observed.
Other detection reagents (HRP-linked anti-biotin anti-
body from CST; strepavidin-HRP from R&D systems)
were less sensitive, and higher concentration of the strep-
tavidin-HRP conjugate resulted in higher background in
empty wells. The reaction was then stopped by adding 50
μl/well 1 M HCl, and plates were read at 450 nm (refer-
ence wavelength 620 nm). After each incubation step,
plates were washed 4 times with PBS, pH 7.4, 0.1%
Tween-20. Antibody and antigen were diluted in PBS.
ELISA format based on streptavidin-coated plates
Reacti-Bind™ Streptavidin High Binding Capacity Coated
96-Well Plates (Pierce; Rockford, IL, USA) were loaded
with the indicated concentrations of the biotinylated
peptides (100 μL/well) and incubated at RT for 2 h.
After washing, bound phosphopeptide was detected with
rabbit anti TAU(pT212) antibody (1:16.000) and HRP-
linked goat anti rabbit IgG (Fc) (Pierce) (1:40.000) and
TMB substrate as described above. PBS with 2% BSA
and 0.1% Tween-20 was used for plate washing and for
dilution of antigen and antibodies.
Data evaluation and curve fitting
Standard curves of phosphorylated tau peptide and the
graphical representation of the time course shown in
Figure 4 were generated by non-linear curve fitting
using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA, USA).
Additional file 1: Figure S1. This PDF file contains a supplementary
figure that shows a multiple sequence alignment of human and Xenopus
laevis DYRK1 isoforms.
Acknowledgements
We are grateful to the members of the Schmalzing group for the gift of the
Xenopus oocytes and to Ulf Soppa for critical reading of the manuscript. This
work was supported by the Deutsche Forschungsgemeinschaft (Be 1967/2-2
and Be 1967/3-1).
Authors’ contributions
EL designed and carried out most of the experiments and analysed the
results. KK carried out the experiments with Xenopus DYRK1. WB conceived
of and coordinated the study and wrote the manuscript. All authors read
and approved the final manuscript.
Received: 4 December 2009 Accepted: 20 May 2010
Published: 20 May 2010
References
1. Ishida A, Kameshita I, Sueyoshi N, Takanobu T, Taniguchi T, Shigeri Y:
Recent advances in technologies for analyzing protein kinases. J
Pharmacol Sci 2007, 103:5-11.
2. Jia Y, Quinn CM, Kwak S, Talanian RV: Current in vitro kinase assays; the
quest for a universal format. Curr Drug Discov Technol 2008, 5:59-69.
3. Witt JJ, Roskoski R Jr: Rapid protein kinase assay using phosphocellulose-
paper absorption. Anal Biochem 1975, 66:253-258.
4. Glass DB, Masaracchia RA, Feramisco JR, Kemp BE: Isolation of
phosphorylated peptides and proteins on ion exchange papers. Anal
Biochem 1978, 87:566-575.
5. Olive DM: Quantitative methods for the analysis of protein
phosphorylation in drug development. Expert Rev Proteomics 2004,
1:327-341.
6. Yano T, Taura C, Shibata M, Hirono Y, Ando S, Kusubata M, Takahashi T,
Inagaki M: A monoclonal antibody to the phosphorylated form of glial
fibrillary acidic protein: application to a non-radioactive method for
measuring protein kinase activities. Biochem Biophys Res Commun 1991,
175:1144-1151.
7. Farley K, Mett H, McGlynn E, Murray B, Lydon NB: Development of solid-
phase enzyme-linked immunosorbent assays for the determination of
epidermal growth factor receptor and pp60c-src tyrosine protein kinase
activity. Anal Biochem 1992, 203:151-157.
8. Yu JS, Chang SH, Chan WH, Chen HC: Enzyme-linked immunosorbent
assay for the determination of p21-activated kinase activity. J Biochem
2001, 29:243-251.
9. Lehel C, Daniel-Issakani S, Brasseur M, Strulovici B: A chemiluminescent
microtiter plate assay for sensitive detection of protein kinase activity.
Anal Biochem 1997, 244:340-346.
10. Ross H, Armstrong CG, Cohen P: A non-radioactive method for the assay
of many serine/threonine-specific protein kinases. Biochem J 2002,
366:977-981.
11. Martin SG, Berthelot-Grosjean M: Polar gradients of the DYRK-family
kinase Pom1 couple cell length with the cell cycle. Nature 2009,
459:852-856.
12. Moseley JB, Mayeux A, Paoletti A, Nurse P: A spatial gradient coordinates
cell size and mitotic entry in fission yeast. Nature 2009, 459:857-860.
13. Stitzel ML, Pellettieri J, Seydoux G: The C. elegans DYRK Kinase MBK-2
Marks Oocyte Proteins for Degradation in Response to Meiotic
Maturation. Curr Biol 2006, 16:56-62.
14. Qu Y, Adler V, Chu T, Platica O, Michl J, Pestka S, Izotova L, Boutjdir M,
Pincus MR: Two dual specificity kinases are preferentially induced by
wild-type rather than by oncogenic RAS-P21 in Xenopus oocytes. Front
Biosci 2006, 11:2420-2427.
Lilienthal et al. BMC Biochemistry 2010, 11:20
http://www.biomedcentral.com/1471-2091/11/20
Page 9 of 10
15. Tejedor F, Zhu XR, Kaltenbach E, Ackermann A, Baumann A, Canal I,
Heisenberg M, Fischbach KF, Pongs O: minibrain: a new protein kinase
family involved in postembryonic neurogenesis in Drosophila. Neuron
1995, 14:287-301.
16. Hämmerle B, Elizalde C, Galceran J, Becker W, Tejedor FJ: The MNB/DYRK1A
protein kinase: neurobiological functions and Down syndrome
implications. J Neural Transm Suppl 2003, 67:129-137.
17. Dierssen M, de Lagrán MM: DYRK1A (dual-specificity tyrosine-
phosphorylated and -regulated kinase 1A): a gene with dosage effect
during development and neurogenesis. ScientificWorldJournal 2006,
6:1911-1922.
18. Becker W: DYRK1A. UCSD-Nature Molecule Pages 2008.
19. Yoshida K: Role for DYRK family kinases on regulation of apoptosis.
Biochem Pharmacol 2008, 76:1389-1394.
20. Friedman E: Mirk/Dyrk1B in cancer. J Cell Biochem 2007, 102:274-279.
21. de la Luna S, Estivill X: Cooperation to amplify gene-dosage-imbalance
effects. Trends Mol Med 2006, 12:451-454.
22. Park J, Song WJ, Chung KC: Function and regulation of Dyrk1A: towards
understanding Down syndrome. Cell Mol Life Sci 2009, 66:3235-3240.
23. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, Proud CG: The
kinase DYRK phosphorylates protein-synthesis initiation factor
eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at
Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming
kinase. Biochem J 2001, 355:609-615.
24. Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, Kim IS,
Cheon YH, Ahn YS, Chung SH, Song WJ: DYRK1A-mediated
hyperphosphorylation of Tau. A functional link between Down
syndrome and Alzheimer disease. J Biol Chem 2007, 282:34850-34857.
25. Kuhn C, Frank D, Will R, Jaschinski C, Frauen R, Katus HA, Frey N: DYRK1A is
a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem
2009, 284:17320-17327.
26. Leder S, Czajkowska H, Maenz B, De Graaf K, Barthel A, Joost HG, Becker W:
Alternative splicing variants of dual specificity tyrosine phosphorylated
and regulated kinase 1B exhibit distinct patterns of expression and
functional properties. Biochem J 2003, 372:881-888.
27. Forrer P, Tamaskovic R, Jaussi R: Enzyme-linked immunosorbent assay for
measurement of JNK, ERK, and p38 kinase activities. Biol Chem 1998,
379:1101-1111.
28. Kinoshita-Kikuta E, Aoki Y, Kinoshita E, Koike T: Label-free kinase profiling
using phosphate affinity polyacrylamide gel electrophoresis. Mol Cell
Proteomics 2007, 6:356-366.
29. Illenberger S, Zheng-Fischhöfer Q, Preuss U, Stamer K, Baumann K,
Trinczek B, Biernat J, Godemann R, Mandelkow EM, Mandelkow E: The
endogenous and cell cycle-dependent phosphorylation of tau protein in
living cells: implications for Alzheimer’s disease. Mol Biol Cell 1998,
9:1495-1512.
30. Hämmerle B, Vera-Samper E, Speicher S, Arencibia R, Martínez S, Tejedor FJ:
Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in
neural progenitor cells at the transition to neurogenic divisions. Dev Biol
2002, 246:259-273.
31. Nissen RM, Amsterdam A, Hopkins N: A zebrafish screen for craniofacial
mutants identifies wdr68 as a highly conserved gene required for
endothelin-1 expression. BMC Dev Biol 2006, 6:28.
32. Goyard S, Knechtle P, Chauvel M, Mallet A, Prévost MC, Proux C, Coppée JY,
Schwartz P, Dromer F, Park H, Filler SG, Janbon G, d’Enfert C: The Yak1
kinase is involved in the initiation and maintenance of hyphal growth in
Candida albicans. Mol Biol Cell 2008, 19:2251-2266.
33. Canzonetta C, Mulligan C, Deutsch S, Ruf S, O’Doherty A, Lyle R, Borel C,
Lin-Marq N, Delom F, Groet J, Schnappauf F, De Vita S, Averill S, Priestley JV,
Martin JE, Shipley J, Denyer G, Epstein CJ, Fillat C, Estivill X, Tybulewicz VL,
Fisher EM, Antonarakis SE, Nizetic D: DYRK1A-dosage imbalance perturbs
NRSF/REST levels, deregulating pluripotency and embryonic stem cell
fate in Down syndrome. Am J Hum Genet 2008, 83:388-400.
34. Himpel S, Tegge W, Frank R, Leder S, Joost HG, Becker W: Specificity
determinants of substrate recognition by the protein kinase DYRK1A. J
Biol Chem 2000, 275:2431-2438.
35. Schmalzing G, Gloor S, Omay H, Kröner S, Appelhans H, Schwarz W: Up-
regulation of sodium pump activity in Xenopus laevis oocytes by
expression of heterologous beta 1 subunits of the sodium pump.
Biochem J 1991, 279:329-336.
36. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost HG: Sequence
characteristics, subcellular localization, and substrate specificity of DYRK-
related kinases, a novel family of dual specificity protein kinases. J Biol
Chem 1998, 273:25893-25902.
37. Göckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W:
Harmine specifically inhibits protein kinase DYRK1A and interferes with
neurite formation. FEBS J 2009, 276:6324-6337.
doi:10.1186/1471-2091-11-20
Cite this article as: Lilienthal et al.: Development of a sensitive non-
radioactive protein kinase assay and its application for detecting DYRK
activity in Xenopus laevis oocytes. BMC Biochemistry 2010 11:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lilienthal et al. BMC Biochemistry 2010, 11:20
http://www.biomedcentral.com/1471-2091/11/20
Page 10 of 10
